GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations

Author： Jespersen Maria J Knop Filip K Christensen Mikkel

ISSN： 1742-5255

Source： Expert Opinion on Drug Metabolism and Toxicology, Vol.9, Iss.1, 2013-01, pp. : 17-29

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations

By Scheen André J

Expert Opinion on Drug Metabolism and Toxicology, Vol. 10, Iss. 5, 2014-05 ,pp. : 647-663

Informa Healthcare

Access to resources Recommend Favorite

GLP-1 agonists: a new approach for type 2 diabetes

Inpharma, Vol. 1, Iss. 1407, 2003-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors

By Holst Jens Juul

Expert Opinion on Emerging Drugs, Vol. 9, Iss. 1, 2004-05 ,pp. : 155-166

Informa Healthcare

Access to resources Recommend Favorite

A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes

By Montanya Eduard

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 10, 2012-07 ,pp. : 1451-1467

Informa Healthcare

Access to resources Recommend Favorite

Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors

By Ahrén Bo

European Diabetes Nursing, Vol. 10, Iss. 1, 2013-03 ,pp. : 31-36

Blackwell Publishing

Access to resources Recommend Favorite